Determinants of response to antibiotic therapy

Journal of Chemotherapy

Volumn 10, Issue 5, 1998, Pages 347-353

  Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antibiotic interactions; Immune system; In vitro susceptibility testing; Pharmacodynamics; Resistance to antibiotics; Sensitivity testing; Susceptibility testing

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFOPERAZONE; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; LATAMOXEF; MEROPENEM; PIPERACILLIN; TEICOPLANIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; DRUG DNA INTERACTION; EDITORIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; POSTANTIBIOTIC EFFECT; PREDICTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031795836     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.5.347     Document Type: Editorial

References (62)

1. Shann F. Pneumococcal vaccine: time for another controlled trial. Lancet 1998; 351: 1600-1601.
2. Haque K. Should intravenous immunoglobulins be used in the treatment of neonatal sepsis? Br J Intensive Care 1997: Jan/Feb; 12-13.
3. Luzuriaga K. Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lawson M. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343-1349.
4. Schneider CM, Daschner FD. Colony-stimulating factors and antibiotics - a new prospect in treating infectious diseases? Clin Microbiol Infect 1998; 4: 119-122.
5. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-933
6. Vincent J-L. Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351: 922-923.
7. Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 24, 7: 1095-1100.
8. Wenisch C, Parschalk B, Hasenhünd M, Wiesinger E, Graninger W. Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicrob Agents Chemother 1995; 39: 672-676.
9. Patchen ML, Brook I, Elliott TB, Jackson WE. Adverse effects of pefloxacin in irradiated C3H/He N mice: correction with glucan therapy. Antimicrob Agents Chemother 1993; 37: 1882-1885.
10. Labro MT. The prohost effect of antimicrobial agents as a predictor of clinical outcome. J Chemother 1997; 9 (suppl 1): 100-108.
11. Bergogne-Berezin, E. Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. J Chemother 1997; 9 (suppl 1): 109-115.
12. Den Hollander JG, Fuursted K, Verbrugh HA, Mouton JW. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 1998; 42: 749-754.
13. Jaffé A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
14. Casey LC. Antibiotics: more than just "bug" killers. Crit Care Med 1997; 8: 1270-1271.
15. Galley HF, Nelson SJ, Dubbels AM, Webster NR. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8 and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 8: 1392-1395.
16. Hartman G, Wise R. Quorum sensing: potential means of treating gram-negative infections? Lancet 1998; 351: 848-849.
17. Trautmann M, Zick R, Rukavina T, Cross AS, Marre R. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother 1998; 41: 163-169.
18. Hurley JC. β-lactam antibiotic-induced release of free lipopolysaccharide. J Infect Dis 1993; 167: 775.
19. Jackson JJ. Reply. J Infect Dis 1993; 167: 775-776.
20. Arditi M, Kabat W, Yogev R. Antibiotic-induced bacterial killing stimulates tumor necrosis factor- release in whole blood. J Infect Dis 1993; 167: 240-244.
21. Lamp KC, Rybak MJ, McGrath B, Summers KK. Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 247-252.
22. Nwariaku FE, McIntyre KL, Sikes PJ, Mileski WJ. The effect of antimicrobial agents on the induction of tumour necrosis factor by alveolar macrophages in vitro in response to endotoxin. J Antimicrob Chemother 1997; 39: 265-267.
23. Takahashi K, Narita K, Kato Y, et al. Low level release of shiga like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother 1997; 41: 2295-2296.
24. Kragsbjerg P, Söderquist B, Holmberg H, Vikerfors T, Danielsson D. Production of tumor necrosis factor- and interleukin-6 in whole blood stimulated by live Gram-negative and Gram-positive bacteria. Clin Microbiol Infect 1997; 4: 129-134.
25. van Langevelde P, Kwappenberg KMC, Groeneveld PHP, Mattie H, van Dissel JT. Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 1998; 42: 739-743.
26. Gould IM, MacKenzie FM. The response of Enterobacteriaceae to β-lactam antibiotics - "round forms, filaments and the root of all evil". J Antimicrob Chemother 1997; 40: 495-499.
27. Rekke O, Sveen G, Lehmann AK, Digranes A, Halstensen A. Endotoxin and cytokines in plasma and clinical manifestations during treatment of septicaemia with impenem or cefuroxime/metronidazole. Immunol Infect Dis 1996; 6: 159-166
28. Basoli A, Meli EZ, Mazzocchi P, Speranza V, & Study Group. Imipenem/cilastatin (1.5g daily) versus meropenem (3.0g daily) in patients with intra-abdominal infections: results of a prospective, randomoized, multicentre trial. Scand J Infect Dis 1997; 29: 503-508.
29. Schneider CM, Huzly D, Vetter C, von Specht BU, Daschner FD. Tumor necrosis factor alpha and interleukin 6 release induced by antibiotic killing of Pseudomonas aeruginosa and Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1997; 16: 467-471
30. Yokoshi T, Kusumi A, Kido N et al. Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide. Antimicrob Agents Chemother 1996; 40: 2410-2412.
31. Keil S, Wiedemann B. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother 1997; 41: 1215-1219.
32. Fuchs PC, Stickel S, Anderson PH, Barry AL, Shilling S. In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactan-beta-lactam combinations. Antimicrob Agents Chemother 1991; 35: 182-184.
33. Neilly IJ, Dawson AA, Golder DA, Gould IM. Absorption of ciprofloxacin after oral administration to leukaemic patients with presumed septicaemia. Antiinfect Drugs Chemother 1995; 13: 215-218.
34. Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 1995; 36: 773-780.
35. Jones EM, McMullin CM, Hedges AJ, et al. The pharmacokinetics of intravenous ciprofloxacin 400mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40: 121-124.
36. Scaglione F, Demertini G, Arcidiacono MM, Dugnani S, Fraschini F. Influence of protein binding on the pharmacodynaimics of ceftazidime or ceftriaxone against Gram-positive and Gram-negative bacteria in an in vitro infection model. J Chemother 1998; 10: 29-34.
37. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995; 39: 1842-1847.
38. Gould IM. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. J Chemother 1997; 9: 74-83.
39. Fuentes F, Izquierdo J, Martin MM, Gomez-Lus ML, Prieto J. Post antibiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. Antimicrob Agents Chemother 1998; 42: 414-418.
40. Lutsar I, Ahmed A, Friedland IR, et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1997; 41: 2414-2417.
41. Gould IM, Milne K, Harvey G, Jason AC. Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin. J Antimicrob Chemother 1991; 27: 741-748.
42. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37; 1073-1081.
43. Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 45-57.
44. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997; 9: 64-73.
45. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527.
46. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine 3rd edn. Baltimore: Williams & Wilkins, 1991: 403-431.
47. Craig W, Ebert S, Watanabe Y. Differences in time above MIC (T>MIC) required for efficacy of beta-lactams in animal infection models. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. LA, 1993 American Society for Microbiology, Washington, DC. 1993: Abstract 86 p 135.
48. Eagle H, Fleischman R, Levy M. The effect of the interval between injections on therapeutic efficacy. N Engl J Med 1953; 248: 480-488.
49. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
50. Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome by experimental infections caused by Escherichia coli. J Antimicrob Chemother 1990; 25: 621-627.
51. Kessler RE, Bies M, Buck RE et al. Comparison of a new cephalosporin. BMY 28142, with other broad spectrum β-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207-216.
52. Hobson RP, Gould IM. Aminoglycoside resistance. Antiinfect Drugs Chemother 1995; 13: 143-147.
53. Sanders CC, Sanders WE Jr. Clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830-836.
54. MacKenzie FM, Gould IM. Extended spectrum β-lactamases - commentary. J Infect 1998; 36: 255-258.
55. Chadwick PR, Brown DEJ, Wilcox MH, et al. Comparison of agar-based media for primary isolation of glycopeptide-resistant enterococci. Clin Microbiol Infect 1997; 3: 559-563.
56. Paterson DL, Ko WC, Mohapatra S, et al. ESBL+ K. pneumoniae bacteraemia. 37th ICAAC 1997; Abstract no J210.
57. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community acquired bacteraemia due to urinary tract infection. J Infect 1997; 35: 283-288.
58. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital acquired bacteraemia in a large teaching hospital in the United Kingdom. Quart J Med 1987; 241: 427-440.
59. Price J, Ekleberyy A, Johnson M, Melendy S, Villaba M, Zervos MJ. Evaluation of clinical practice guidelines on infection outcome and antibiotic resistance in an Intensive Care Unit. 37th ICAAC 1997; Abstract no J131.
60. Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EG. The impact of blood culture reporting and clinical liaison on the empiric treatment of bacteraemia. J Clin Pathol 1997; 50: 1010-1012.
61. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. J Am Med Assoc 1996; 275: 234-240.
62. Shackley P, Cairns J, Gould IM. Accelerated bacteriological evaluation in the management of lower respiratory tract infection in general practice. J Antimicrob Chemother 1997; 39: 663-666.